

Bridging gaps between Respiratory care guidelines, optimising outcomes for patients with uncontrolled ASTHMA



Chiesi Limited and Health Innovation Oxford and Thames Valley

This executive summary of the BRIDGE-ASTHMA Project within the Respiratory Transformation Partnership has been written by Chiesi Limited with consultation and approval from the Collaborative Working Project Team, established with full representation of both partners.

BRIDGE ASTHMA Project Aims:

The overall ambition of this collaborative working project is to support uncontrolled asthma patients by creating a standardised Asthma Optimisation Framework.

This collaborative project will also support the pilot implementation in up to 8,000 patients across 4 NHS sites (NHS Cheshire and Merseyside ICB, NHS Greater Manchester ICB, NHS Leicester, Leicestershire and Rutland ICB, NHS Black Country ICB).

Intended Benefits:

For patients:

- Ensure uncontrolled asthma patients receive high quality care, optimising pharmacological management to avoid un-necessary secondary care referrals.
- Reduction in asthma exacerbation rate and healthcare utilisation by optimisation of treatment and patient compliance to inhalers.
- Supports optimal disease control and improved health related quality of life.
- Enhancing the correct use of inhalers through education and support.

For NHS:

- Ensure consistency of care across the NHS for the management on uncontrolled asthma patients.
- Improved patient outcomes resulting in less demand for primary care resource, urgent and emergency care services, and non-elective hospital admission.
- Ensure NHS budgets are optimised by ensuring patients optimally benefit from treatments.

- Increased ability to optimise management of uncontrolled asthma patients in primary care, reducing inappropriate secondary care referrals and thereby increasing capacity for secondary care to manage severe or difficult asthma.
- Faster access to secondary care for appropriate severe or difficult asthma patients, facilitating the initiation of relevant patients onto biologics.

For the industry partner:

- Increase in the appropriate use of medicines aligned to local or national guidance
- Better understanding of the challenges faced by the NHS in delivering high-quality patient care
- Reputational gain associated with supporting improvements in NHS services and care

Resource Contributions:

BRIDGE-ASTHMA project is associated with combined investment is £1.175 million, comprising £675,000 from Chiesi Limited and £500,000 from Health Innovation Oxford & Thames Valley, demonstrating a substantial joint commitment to improving management of uncontrolled asthma patients, capability development and pathway transformation.

Table 1: Overall BRIDGE-ASTHMA Project Contribution breakdown

Contribution Type	Chiesi Limited	HIOTV	Overall Total
Financial Contribution	£575,000	£200,000	£775,000
In-Kind (Time) Contribution	£100,000	£300,000	£400,000
Total Contribution	£675,000	£500,000	£1,175,000
% of Total Programme Contribution	57%	43%	100%

The RTP programme will last 2 years and commence April 2026

The BRIDGE-ASTHMA Project will support the development of the framework between July and December 2026 and operational projects for 12 months from January 2027